New CEO for Polyplus-transfection Polyplus-transfection, a leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, named Mario Philips as Chief Executive Officer. He succeeds Karsten Wilking, who will transition into a strategic advisor role. Prior to this appointment, Mario Philips served as CEO of…..
EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment
EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics, a german biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement to facilitate the company’s development and clinical testing of…..
Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending full, or standard, marketing authorization for Libmeldy® (cryopreserved autologous CD34+ cells encoding the arylsulfatase-A, or ARSA,…..
NIH begins large clinical trial to test immune modulators for treatment of COVID-19 The National Institutes of Health (NIH) has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response…..
Trend Chart On Innovative Bioindustries September 2020, 17th FEATURE STORY ● Nonclinical studies that support viral vector-delivered gene therapies: An EFPIA Gene Therapy Working Group perspective BASIC SCIENCE ● Paving the road for RNA therapeutics CLINICAL TRIALS/DATAS ● Akcea: Positive phase 2 clinical data of Vupanorsen ● The NEJM publishes…..
Clean Cells et Xenothera, deux acteurs d'Atlanpole Biothérapies dans la lutte contre le SARS-COV-2 La CDMO vendéenne Clean Cells a mis au point un test RT-qPCR dédié à la détection et à la quantification du SARS-CoV-2 dans les substances actives ou les produits finis dédiés aux industries de la santé…..
G&CTI, premier think tank indépendant sur les thérapies avancées Dans l’environnement actuel où les thérapies géniques et cellulaires apparaissent certes comme une véritable révolution médicale, mais où de nombreux défis éthiques, sociétaux, politiques, économiques se posent, la quête de réponses opérationnelles s’impose ! L’ensemble des acteurs (sociétés savantes, patients, industriels,…..
Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics Agilent Technologies will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and RNA molecules used to create nucleic acid-based therapeutics. Oligos hold the potential to be used in developing treatments for…..
Evotec-Secarna: new partnership in antisense oligonucleotide-based therapeutics The German companies Evotec and Secarna Pharmaceuticals have concluded a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Secarna, a global leader in discovering and developing next-generation ASO, combines its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate…..
HexaPro: a new tool to speed up Covid-19 vaccine production ? Most coronavirus vaccine candidates train the human immune system to recognize the spike protein on the surface of the SARS-CoV-2 virus in order to fight infection. A scientific team at The University of Texas at Austin has successfully redesigned…..
- Page Précédente
- 1
- 2
- 3
- 4
- 5
...
- 30
- Page Suivante
Partenaires
